Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Endovia Health Sciences, Inc.

NYSE: EDVA · Manufacturing · 6 alerts · CIK 1553788

Share price
$0.1710Close, Nov 16
Market cap
$1.1M
Shares outstanding
6.41MLatest SEC cover page
Sector
Manufacturing
Industry
BeveragesSIC 2080

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Endovia Health Sciences, Inc. filings on SEC EDGAR ↗

4:11 PM ET 8-K
Capital Raise

Endovia Health Sciences Capital Raise

Endovia Health Sciences entered into an addendum to its existing equity line of credit (ELOC) with C/M Capital Master Fund, LP, increasing the maximum commitment from $35 million to $135 million. The agreement allows the company to sell and issue shares of common stock to the fund from time to time, providing a significant increase in potential liquidity. The addendum also updates terms for sales exceeding the initial 10.875 million shares issued under the original facility.

Counterparty
C/M Capital Master Fund, LP
4:11 PM ET 8-K
Other 8-K Filing

Endovia Health Sciences Other 8-K Filing

Endovia Health Sciences entered into a letter agreement with C/M Capital Master Fund, LP to amend an existing equity line of credit facility. The amendment increases the beneficial ownership limitation for the investor from 4.99% to 9.99% and waives certain notice requirements. This administrative change modifies the terms of a previously established financing vehicle without disclosing a new capital draw.

Counterparty
C/M Capital Master Fund, LP
4:10 PM ET 8-K
Capital Raise

Endovia Health Sciences Capital Raise

Endovia Health Sciences issued 526,582 shares of common stock to C/M Capital Master Fund, LP for gross proceeds of approximately $81,831. The issuance was conducted under an existing equity line of credit (ELOC) agreement dated September 19, 2025.

Counterparty
C/M Capital Master Fund, LP
4:02 PM ET 8-K
Regulatory Approval

Endovia Health Sciences Regulatory Approval

Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined its investigational drug CannEpil qualifies as a 'minor use' under the MUMS program for canine bone cancer pain. This designation allows the company to pursue a conditional approval pathway, which facilitates earlier market availability while additional effectiveness data is collected. The company is targeting a potential U.S. veterinary product launch in 2027.

Counterparty
Lupvindol BioSciences
4:12 PM ET 8-K
Capital Raise

Endovia Health Sciences Capital Raise of $1.32M

Endovia Health Sciences entered into a letter agreement with C/M Capital Master Fund for a minimum $1 million investment commitment, closing an initial $510,000 via a secured convertible promissory note. Additionally, the company disclosed the issuance of 3,629,250 shares of common stock for gross proceeds of approximately $808,829 under an existing equity line of credit. The funds will support the regulatory advancement and commercialization of CannEpil®.

Value
$1.32M
Counterparty
C/M Capital Master Fund, LP
4:11 PM ET 8-K
Loan & Debt

Endovia Health Sciences $500K Debt Financing with C/M Capital Master Fund, LP

Endovia Health Sciences closed an initial $500,000 tranche of secured convertible debt funding from C/M Capital Master Fund, LP. This financing is part of a larger $1 million commitment intended to accelerate the development and commercialization of CannEpil®, the company's cannabinoid-based pharmaceutical asset.

Value
$500K
Counterparty
C/M Capital Master Fund, LP

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.